UroGen Pharma Ltd. (NASDAQ:URGN) Q3 2024 Earnings Call Transcript November 6, 2024
UroGen Pharma Ltd. beats earnings expectations. Reported EPS is $-0.55, expectations were $-0.82.
Operator: Good morning, ladies and gentlemen. Thank you for standing by and welcome to the UroGen Pharma Third Quarter 2024 Earnings Call. Please be advised that today’s conference is being recorded. I would now like to hand the conference over to your speaker today, Vincent Perrone, Head of Investor Relations....
